Benzoyl Peroxide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Benzoyl Peroxide: From Acne Vulgaris to Vulvar Inverted Follicular Keratosis
One-Sentence Summary
Benzoyl peroxide (BPO) is a well-established topical antimicrobial and keratolytic agent, widely used internationally for the treatment of acne vulgaris, though it currently holds no SAHPRA registration in South Africa. The TxGNN model predicts it may have potential in Vulvar Inverted Follicular Keratosis, a rare benign follicular keratinisation tumour of the vulvar epithelium. However, there are currently 0 clinical trials and 0 publications directly supporting this prediction, placing this candidate at the lowest evidence tier (L5).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acne vulgaris (established international use; not registered with SAHPRA) |
| Predicted New Indication | Vulvar Inverted Follicular Keratosis |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why Is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, benzoyl peroxide is a topical oxidising agent that releases reactive oxygen species upon contact with skin, exerting both antimicrobial activity against Cutibacterium acnes and a direct keratolytic effect on the follicular epithelium. These dual properties underpin its well-established global use in inflammatory and non-inflammatory acne vulgaris.
Vulvar inverted follicular keratosis (VIFK) is a rare benign tumour arising from the infundibular follicular epithelium, characterised pathologically by endophytic growth, squamous eddies, and abnormal keratinisation. The TxGNN prediction most likely reflects a knowledge-graph category association between the node cluster “keratinising skin disease” and the node cluster “keratolytic/oxidising agent” — mechanistically plausible in a broad sense, but without any specific biological or clinical anchor to VIFK.
The anatomical context substantially weakens this prediction: the vulvar epithelium is highly sensitive mucosal or perimucosal tissue, and BPO at standard therapeutic concentrations (2.5–10%) is well known to cause significant oxidative irritation on sensitive surfaces. The theoretical keratolytic rationale does not translate into a clinically viable treatment pathway for a benign follicular tumour of this anatomical site. This prediction should be regarded as a model artefact rather than a true repurposing signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Benzoyl peroxide is not currently registered with SAHPRA and holds no active product licences in South Africa. No approved indications, dosage forms, or registration numbers are on record.
Healthcare professionals wishing to use benzoyl peroxide in South Africa for any indication would need to apply for a Section 21 unregistered medicine authorisation through SAHPRA prior to use.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note for prescribers: Although detailed safety data was not retrievable in this evidence pack, it is widely documented that benzoyl peroxide is a potent contact irritant and known cutaneous sensitiser. Its application to mucosal or perimucosal surfaces (such as the vulva) carries a substantive risk of severe local irritation and contact dermatitis that would need to be carefully weighed before any off-label use is considered.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no clinical or preclinical evidence supporting benzoyl peroxide for vulvar inverted follicular keratosis, and the prediction is most likely driven by a non-specific knowledge-graph association between keratolytic agents and keratinising lesions rather than any direct mechanistic or empirical link. The anatomical target (vulvar mucosa) further raises significant tolerability concerns for a potent oxidising compound.
To proceed, the following is needed:
- Retrieve full mechanism of action data from DrugBank (DB09096) and a SAHPRA/FDA-approved Professional Information document to characterise the complete pharmacological and safety profile
- Conduct a targeted literature review for BPO activity against any benign follicular keratinisation tumour, including case reports or in vitro studies, to determine whether a preclinical signal exists
- Assess mucosal tolerability data (e.g., existing data on perioral or genital mucosa exposure) before any clinical translation is considered
- This candidate should not advance beyond a research question without at minimum one independent preclinical study demonstrating activity in a VIFK-relevant model
This report is generated for research purposes only and does not constitute medical advice. All repurposing candidates require clinical validation before any clinical application. Healthcare professionals should report adverse drug reactions to SAHPRA.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.